Show simple item record

dc.contributor.authorApter, Dan L.pt_BR
dc.contributor.authorWheeler, Cosette M.pt_BR
dc.contributor.authorPaavonen, Jormapt_BR
dc.contributor.authorCastellsague, Xavierpt_BR
dc.contributor.authorGarland, Suzanne M.pt_BR
dc.contributor.authorSkinner, S. Rachelpt_BR
dc.contributor.authorNaud, Paulo Sergio Vieropt_BR
dc.contributor.authorSalmerón, Jorgept_BR
dc.contributor.authorChow, Song-Nanpt_BR
dc.contributor.authorKitchener, Henrypt_BR
dc.contributor.authorTeixeira, Júlio Césarpt_BR
dc.contributor.authorJaisamrarn, Unnoppt_BR
dc.contributor.authorLimson, Genarapt_BR
dc.contributor.authorSzarewski, Annept_BR
dc.contributor.authorRomanowski, Barbarapt_BR
dc.contributor.authorAoki, Fred Y.pt_BR
dc.contributor.authorSchwarz, Tino F.pt_BR
dc.contributor.authorPoppe, Willy A. J.pt_BR
dc.contributor.authorBosch, F. Xavierpt_BR
dc.contributor.authorMindel, Adrianpt_BR
dc.contributor.authorSutter, Philippe dept_BR
dc.contributor.authorHardt, K.pt_BR
dc.contributor.authorZahaf, Toufikpt_BR
dc.contributor.authorDescamps, Dominiquept_BR
dc.contributor.authorStruyf, Frankpt_BR
dc.contributor.authorLehtinen, Mattipt_BR
dc.contributor.authorDubin, Garypt_BR
dc.date.accessioned2015-11-19T02:40:24Zpt_BR
dc.date.issued2015pt_BR
dc.identifier.issn1556-679Xpt_BR
dc.identifier.urihttp://hdl.handle.net/10183/129943pt_BR
dc.description.abstractWe report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV- 16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one vaccine dose (vaccine, n 9,319; control, n 9,325) at months 0, 1, and/or 6. The TVC-naive (vaccine, n 5,822; control, n 5,819) had no evidence of high-risk HPV infection at baseline, approximating adolescent girls targeted by most HPV vaccination programs. Mean follow-up was approximately 39 months after the first vaccine dose in each cohort. At baseline, 26% of women in the TVC had evidence of past and/or current HPV-16/18 infection. HPV-16 and HPV-18 antibody titers postvaccination tended to be higher among 15- to 17-year-olds than among 18- to 25-year-olds. In the TVC, vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or greater (CIN1 ), CIN2 , and CIN3 associated with HPV-16/18 was 55.5% (96.1% confidence interval [CI], 43.2, 65.3), 52.8% (37.5, 64.7), and 33.6% ( 1.1, 56.9). VE against CIN1 , CIN2 , and CIN3 irrespective of HPV DNA was 21.7% (10.7, 31.4), 30.4% (16.4, 42.1), and 33.4% (9.1, 51.5) and was consistently significant only in 15- to 17-year-old women (27.4% [10.8, 40.9], 41.8% [22.3, 56.7], and 55.8% [19.2, 76.9]). In the TVC-naive, VE against CIN1 , CIN2 , and CIN3 associated with HPV-16/18 was 96.5% (89.0, 99.4), 98.4% (90.4, 100), and 100% (64.7, 100), and irrespective of HPV DNA it was 50.1% (35.9, 61.4), 70.2% (54.7, 80.9), and 87.0% (54.9, 97.7). VE against 12-month persistent infection with HPV-16/18 was 89.9% (84.0, 94.0), and that against HPV-31/33/45/51 was 49.0% (34.7, 60.3). In conclusion, vaccinating adolescents before sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up to 18 years of age is most likely effective.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofClinical and vaccine immunology. Washington. Vol. 22, no. 4 (Apr. 2015), p. 361-373pt_BR
dc.rightsOpen Accessen
dc.subjectPapillomavirus humano 16pt_BR
dc.subjectAdulto jovempt_BR
dc.subjectMulherespt_BR
dc.subjectMétodo duplo-cegopt_BR
dc.titleEfficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04- adjuvanted vaccine against cervical infection and precancer in young women : final event-driven analysis of the randomized, double- blind PATRICIA trialpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000970564pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record